June 27, 2014 by Brad Perriello
Geoff Martha, the executive in charge of integrating Medtronic’s $43 billion Covidien acquisition, tells MassDevice.com that the deal will likely mean more strategic investments for the medical device giant.
The pending $43 billion merger of Medtronic (NYSE:MDT) andCovidien (NYSE:COV) triggered speculation that the combined medical device giant would scale back on its strategic investment program. After all, there’s a lot to digest in integrating a buyout of that size, the thinking goes, and the move likely takes 2 prolific acquirers off the board.
But the opposite is true, according to Geoff Martha, the Medtronic strategy & business development executive charged with managing the integration of Covidien.
